Price$4.64+0.38 (+8.92%)
01:30 PM07:45 PM
News · 26 weeks29-14%
2025-10-262026-04-19
Mix1490d
- SEC Filings4(29%)
- Other3(21%)
- Insider3(21%)
- Earnings1(7%)
- Leadership1(7%)
- Analyst1(7%)
- Other1(7%)
Latest news
25 items- PRLifeMD® Now Offering Eli Lilly and Company's Foundayo™ (orforglipron), a New GLP-1 Pill for Weight ManagementNEW YORK, April 10, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced that it is now offering Foundayo™ (orforglipron) to eligible patients through its weight management program. Foundayo, developed by Eli Lilly and Company, is a once daily oral treatment for adults with obesity or overweight with weight-related medical problems. Foundayo is available to eligible LifeMD patients through the Company's integration with LillyDirect®, which enables prescriptions to be fulfilled and shipped directly to patients. The starting self-pay price for Foundayo is $149 per month for the initial dosage. Patients with eligible commer
- INSIDERSEC Form 4 filed by Pisano Christopher A4 - LifeMD, Inc. (0000948320) (Issuer)
- INSIDERSEC Form 3 filed by new insider Pisano Christopher A3 - LifeMD, Inc. (0000948320) (Issuer)
- INSIDERSEC Form 3 filed by new insider Kavthekar Atul3 - LifeMD, Inc. (0000948320) (Issuer)
- SECSEC Form S-8 filed by LifeMD Inc.S-8 - LifeMD, Inc. (0000948320) (Filer)
- PRLifeMD Offers Novo Nordisk's Industry-First Wegovy® Telehealth Subscription ProgramNEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced the launch of Novo Nordisk's new Wegovy® (semaglutide) subscription program — the first and only GLP-1 subscription offering of its kind — now available through LifeMD. The program meaningfully expands patient access to branded GLP-1 therapy and supports treatment adherence with significant cost savings. The subscription model marks a significant evolution in branded GLP-1 distribution. Eligible patients who enroll in the multi-month Wegovy® program through LifeMD now benefit from structured pricing: up to $1,200 in annual savings for injectable for
- PRLifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred StockNEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced that its Board of Directors has authorized a cash dividend to holders of the Company's 8.875% Series A Cumulative Perpetual Preferred Stock (NASDAQ:LFMDP) equal to $0.5546875 per share. The preferred dividend will be paid on April 15, 2026, to holders of record at the close of business on April 3, 2026. About LifeMD, Inc.LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men's and women's hea
- SECLifeMD Inc. filed SEC Form 8-K: Leadership Update8-K - LifeMD, Inc. (0000948320) (Filer)
- ANALYSTLifeMD upgraded by Mizuho with a new price targetMizuho upgraded LifeMD from Neutral to Outperform and set a new price target of $8.00
- PRLifeMD Appoints Veteran Healthcare Finance Executive as Chief Financial Officer and Expands Leadership TeamNEW YORK, March 16, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced the appointment of Atul Kavthekar as Chief Financial Officer, effective today. The Company also announced leadership changes to support its next phase of growth. Marc Benathen, the Company's current CFO, is departing to pursue a new opportunity and will remain with LifeMD through March 31, 2026, to facilitate a smooth transition. "We are thrilled to welcome Atul to LifeMD," said Justin Schreiber, Chairman and CEO of LifeMD. "He is a versatile financial leader who has spent nearly three decades helping healthcare and technology companies scale, and h
- SECSEC Form 10-K filed by LifeMD Inc.10-K - LifeMD, Inc. (0000948320) (Filer)
- SECLifeMD Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - LifeMD, Inc. (0000948320) (Filer)
- PRLifeMD to Participate in Two Investor Conferences During MarchNEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced that management will be participating in the following investor conferences during the month of March: Mizuho Securities Healthcare Technology Conference 2026, March 5. Management will hold virtual one-on-one meetings with investors throughout the day.KeyBanc Capital Markets Healthcare Forum, March 17-18. Management will participate in a virtual fireside chat on Wednesday, March 18th at 9:00 a.m. Eastern time and a virtual panel titled "The Outlook for the GLP-1 Market: New Injection Modalities vs. Orals" at 12:00 p.m. Eastern time. In addition, man
- PRLifeMD to Report Fourth Quarter 2025 Financial Results on March 9NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three and 12 months ended December 31, 2025, after the close of the U.S. financial markets on March 9, 2026, and will host a conference call beginning at 4:30 p.m. Eastern time. Conference Call & Webcast Details Date:Monday, March 9thTime:4:30 p.m. Eastern timeToll-Free Dial-In:800-343-5172International Dial-In:203-518-9856Conference ID:LIFEMDLive & Archived Webcast:Link About LifeMD, Inc. LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy ser
- SECLifeMD Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits8-K - LifeMD, Inc. (0000948320) (Filer)
- PRLifeMD Announces Closing of $50 Million Revolving Credit Facility with Citizens Bank, N.A.NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care and pharmacy services, today announced the closing of a new senior secured revolving credit facility ("RCF") with Citizens Bank, N.A. ("Citizens"). The facility has a maturity date of January 2, 2029 and provides for up to $50 million of total availability consisting of $30 million of committed availability with an additional accordion option of up to $20 million. As of closing, no balance was drawn on the RCF as the Company believes its cash on hand and expected cash flow are sufficient to fund its organic growth initiatives. "We are very pleased to close this revolving cred
- PRLifeMD Expands Collaboration with Novo Nordisk as Recognized Telehealth Partner Offering Newly Approved Wegovy® PillNEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care and pharmacy services, today announced it is now offering Novo Nordisk's Wegovy® (semaglutide) pill – the first and only FDA-approved oral GLP-1 therapy for chronic weight management and cardiovascular health – through its end-to-end telehealth platform. Eligible patients can access the Wegovy® pill for as little as $149 per month, further expanding LifeMD's portfolio of branded obesity treatments. This announcement broadens LifeMD's long-standing collaboration with Novo Nordisk. As part of the relationship, LifeMD is featured on the NovoCare® and Wegovy® websites as a truste
- PRLifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred StockNEW YORK, Dec. 26, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services and pharmacy solutions, today announced that its Board of Directors has authorized a cash dividend to holders of the Company's 8.875% Series A Cumulative Perpetual Preferred Stock (NASDAQ:LFMDP) equal to $0.5546875 per share. The preferred dividend will be paid on January 15, 2026, to holders of record at the close of business on January 5, 2026. About LifeMD, Inc.LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, spanning primary ca
- INSIDERChief Marketing Officer Friedeman Jessica sold $54,158 worth of shares (15,000 units at $3.61), decreasing direct ownership by 7% to 205,000 units (SEC Form 4)4 - LifeMD, Inc. (0000948320) (Issuer)
- PRLifeMD Recognized by the 2025 Deloitte Technology Fast 500™ and by TIME's America's Growth Leaders of 2026NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services and pharmacy solutions, today announced it has been recognized on both the 2025 Deloitte Technology Fast 500™ and the inaugural TIME's America's Growth Leaders of 2026 lists. These distinguished awards reflect LifeMD's continued revenue growth, financial stability, and emerging leadership position in the health technology sector. "Inclusion on these lists of North America's fastest-growing companies is a testament to the strength of our integrated telehealth platform and our ability to meet the increasing demand for accessible, high-quality virtual healthcare. With a
- SECSEC Form 10-Q filed by LifeMD Inc.10-Q - LifeMD, Inc. (0000948320) (Filer)
- SECLifeMD Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - LifeMD, Inc. (0000948320) (Filer)
- PRLifeMD® to Offer Market-Leading Pricing for GLP-1 Medications Wegovy® and Ozempic® in Continued Collaboration with Novo NordiskNEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services and pharmacy, today announced a new, lower cash-pay price for GLP-1 medications, Wegovy® and Ozempic®, made possible through its ongoing collaboration with Novo Nordisk. LifeMD will now offer the 0.25 mg and 0.5 mg doses at $199 per month—the lowest cash-pay pricing available nationwide—for two fills for new patients. The offering is designed to support patients who pay out of pocket. These medications are available through the LifeMD Weight Management Program, which provides comprehensive support including virtual consultations with LifeMD's dedicated clinical team,
- SECSEC Form NT 10-Q filed by LifeMD Inc.NT 10-Q - LifeMD, Inc. (0000948320) (Filer)
- PRLifeMD to Participate in the BTIG Digital Health ForumNEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services and pharmacy, today announced its participation in the virtual BTIG Digital Health Forum on November 24, 2025. Management will participate in a virtual panel discussion titled "Creating a Scalable Virtual Primary Care and Obesity Health Platform" at 4:00 p.m. Eastern time and will be available for one-on-one virtual meetings. Investors can register for the conference by contacting their BTIG representative. About LifeMD, Inc. LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialize